Glycostem enters into Material Transfer Agreement with Pieris to enhance solid tumor targeting capabilities of Glycostem’s oNKord® and CAR-NK treatments
12th March, 2021 – Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf Natural Killer (NK) cells, has entered into a material transfer agreement with Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications to study the potential of Pieris’ Anticalintechnology to enhance the activity of Glycostem’s lead product oNKord®, which is based on non-manipulated NK cells.
Under the terms of the agreement, Pieris will provide Glycostem with Anticalin constructs against immune targets to be combined with Glycostem’s oNKord® technology to study the combined potential of the technologies in the treatment of solid tumors. The parties are also exploring unique NK-based chimeric antigen receptor (CAR-NK) treatments using Glycostem’s CAR-NK technology, viveNKTM, and Pieris’ Anticalin platform to investigate new tumor targeting approaches.
“We look forward to study the potential benefits of combining our NK cell and CAR-NK products with Pieris Anticalin technology in the treatment of solid tumors. We believe these research efforts could lead to novel applications for oNKord® in the field of solid tumor NK cell immunotherapy. Our ultimate goal is to offer these pioneering therapies to patients with the hopes of curing cancer,” said Troels Jordansen, CEO of Glycostem. “Besides, we are glad to reach this significant agreement which marks Glycostem’s first US agreement and confirms our increasing focus on the US market.”